Pfizer, the largest U.S, drugmaker, yesterday abandoned its effort to buy AstraZeneca for $117 billion, saying the public bid rejected by its London-based competitor represented “full value.”
Pfizer, the largest U.S, drugmaker, yesterday abandoned its effort to buy AstraZeneca for $117 billion, saying the public bid rejected by its London-based competitor represented “full value.”